Home
Service offer
Scientific background
R&D pipeline
 
Rat models
Partnership
Corporate overview
 
Scientific Advisory Board
 
Investor's room
We are seeking for...
News room
Contact us
   
 
   
 
Company Profile Board of Directors Advisors
   
  Company Profile
   
 
The development of a new drug costs roughly 800 M.USD. This huge investment has to cover both the development of the drug itself and the cost of unfruitful work. Dead-ends can represent up to 80% of the total cost of a successful drug. Major challenges in the drug development process are (1) to reduce high failure rates due to faulty candidate selection and false positives and (2) to identify all the potential candidates among the false negatives.
There are thus great potential savings to be realized by making development more efficient. To help make these savings, genOway designs, develops and markets technologies and proprietary innovative genetically modified biological models. These solutions aim to increase the predictability and throughput of research in target validation, drug screening and pharmacological - toxicological studies.
   
  Board of Directors
   
 
Jean-Claude Lévêque (represents DASSAULT DEVELOPPEMENT)
Jean-Claude Pignol (represents QUALIS SCA)
   
 
Alexandre Fraichard - MBA HEC – CEO
French. Earned his Ph.D. at the Ecole Normale Supérieure de Lyon in Molecular and Cellular Biology in 1997. Worked for five years on animal models at the ENS where he produced the first model of hypothyroidism and co-founded the Transgenetic Center.
Did an MBA (1998-1999) at the HEC business school (Paris, France) and co-founded genOway in 1999.
 
 
Gilles de Poncins - MBA HEC - CFO
French. Graduated from the Institut d'Etudes Politiques in Paris. Twelve years experience in finance. Head of the risk management department at Renault Crédit International for three years. Investment manager in corporate finance at Qualis (1994 – 1998). Qualis is a private holding company that raised 300 million FRF in 1996. CFO of Sofecome, a French company involved in outsourcing (1996 – 1998). Did an MBA (1998-1999) at the HEC business school (Paris, France) and co-founded genOway in 1999.
 
 
Michel G. Lurquin
Belgian. Former Director & Vice President Europe for Technical Operations at SmithKlineBeecham.
Current Head of
UCBP Global Technical Operations, covering all manufacturing and supply activities worldwide as well as chemical and pharmaceutical development.
Former Expert with the
EBRD (European Bank for Reconstruction and Development). During his career with SB filled a number of positions in Regulatory, Quality and Technical Operations. Actively participating in the development of two other start-ups in the healthcare sector; Bioprofile as a member of the Strategic Committee, Cecami HT as a non-executive director and BioMethodes as associate and Non Executive Director. As part of his assignments with the EBRD, he is also a non-executive director of ZAO Katren Pharmaceuticals (Russia).
 
 
Jean-Claude Lévêque
French. Represents DASSAULT DEVELOPPEMENT.Graduated from HEC and has an MBA in international finance. During time with the CIC (Credit Industriel et Commercial) between 1984 and 1986 originated the first FCPR in France. In 1990 joined Innovacom, an investment fund of France Telecom specialized in financing high-tech start-ups. From 1997 to 1998, Senior Vice-President in charge of foreign merger and acquisition operations. Member of the board of Vision Numeric, Decan, Arche Communications, Business Objects and Infovista.
Joined Dassault Developpement in 1998 as partner.
Secretary of the French Association for the Development of Cellular and Vascular Biology.
 
 
Jean-Claude Pignol
French, former VP of TECHNIP, French company involved in engineering. Has a 25 years experience in the management of small industrial companies in international environment.
 
Advisors
   
 
Auditor & legal advisor Price Waterhouse Coopers have been the company’s auditor since the creation of genOway.
Patent attorney M. Warcoin CEO of Cabinet Regimbeau, a leading European patent attorney is advising the company on its intellectual property policy including patents, licensing out and licensing in.
Corporate advisor Cabinet Mesny (Paris) and Bird&Bird (Paris) are advising the company on corporate and shareholder relations.
   
 

- © genOway 2003 -
A provider in Transgenesis: knock out mouse, knock-in mouse and transgenic mouse